KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to 0.48.

  • Rigel Pharmaceuticals' Equity Ratio rose 56192.08% to 0.48 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48, marking a year-over-year increase of 56192.08%. This contributed to the annual value of 0.02 for FY2024, which is 10820.61% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Equity Ratio stood at 0.48 for Q3 2025, which was up 56192.08% from 0.4 recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Equity Ratio high stood at 0.48 for Q3 2025, and its period low was 0.28 during Q3 2023.
  • For the 5-year period, Rigel Pharmaceuticals' Equity Ratio averaged around 0.02, with its median value being 0.03 (2022).
  • Per our database at Business Quant, Rigel Pharmaceuticals' Equity Ratio plummeted by 73586.15% in 2023 and then skyrocketed by 56192.08% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Equity Ratio (Quarter) stood at 0.18 in 2021, then crashed by 155.86% to 0.1 in 2022, then tumbled by 140.97% to 0.24 in 2023, then skyrocketed by 108.21% to 0.02 in 2024, then surged by 2318.33% to 0.48 in 2025.
  • Its Equity Ratio stands at 0.48 for Q3 2025, versus 0.4 for Q2 2025 and 0.11 for Q1 2025.